Background: Although Inflectra, biosimilar infliximab, has been approved by the EMA since September 2013 for all licensed indications of Remicade (innovator infliximab) but there is a paucity of real-world data and guidelines regarding switching from innovator Remicade to Inflectra. Objectives: To explore efficacy, safety, and retention rate of biosimilar Inflectra when switching from Remicade, in patients with rheumatic diseases. Methods: Informed consent was sought from all patients attending our rheumatology unit to undertake a switching programme. Baseline demographics and clinical characteristics were obtained before switching to Inflectra. Disease activity and safety assessment were undertaken before and then every 12 weeks after switching. The retention rate of Inflectra switch patients was compared with a cohort of non-switch Inflectra naive (11 patients) and historic Remicade (31 patients) patients. Results: Thirty out of thirty-one patients {median (IQR) age 50 (18), 20F} with various rheumatic diseases (9 with diagnosis of AS, 6 with RA, 6 with Behçet's disease, 3 with Enteropathic arthritis, 2 with psoriatic arthritis) agreed to the switch. There was no statistical difference noted between pre-switch and 6 months post-Fortune J Rheumatol 2019; 1 (4) : 040-049 Fortune Journal of Rheumatology 41 switch mean values of PGA (p=0.37), BASDAI (p=0.60), ASDAS-CRP (p=0.90), DAS28CRP (p=0.85), DAS28ESR (p=0.45), CRP (p=0.09), Behçet's disease activity score (p=0.77) and HAQ-DI (p=0.18). The retention rate on Inflectra switch was 86.7% as compared to 90.9% in the Inflectra naive cohort and 100% for historic Remicade cohort. Conclusion: These results demonstrate that in this cohort at 6 months Inflectra is comparable to Remicade in efficacy and there are no new safety signals. Disease activity; Retention rate; Nocebo effect 72 (24-192) 11 (2-26) Concomitant csDMARDs, n (%) 16 (53.3%) 6 (54.5%) Methotrexate, dose, mg, median (range) 15 (10-25) 15 (10-25) Concomitant corticosteroids, n (%) 9 (30%) 6 (54.5%) Previously been on other bDMARDS, n (%) 19 (63.3%) 11 (100%)
Introduction
Undoubtedly biological DMARDs (bDMARDs), including TNF-alpha inhibitors, have revolutionized the treatment of various rheumatic disorders such as AS, RA, and psoriatic arthritis [1] [2] [3] and these have become an integral component of treatment algorithms of these diseases [4, 5] . However huge costs associated with the use of bDMARDs have been a barrier to their widespread use and accessibility especially in the countries with the low gross domestic product [6, 7] . A European study has shown that bDMARDs cannot be reimbursed in some countries within Europe and bDMARDs treatment costs were more than the actual GDP in 26 countries [6] . It is anticipated that availability of biosimilar DMARDs (bsDMARDs) will reduce the economic burden and accessibility to biologics due to reduced cost and the addition of competition to the market [8] . Biosimilars are biological medicinal agents that contain a version of active substance of reference biological product, also called originator or reference biologics, are supposed to be administered at the similar dose to treat same disorders [9] . Due to large size and complex structure, an exact copy of reference biologic is not possible. There is a rigorous process required to establish that a biosimilar product is similar to the reference product in terms of 
Methods

Patients and study design
Statistical analysis
The data were analysed using SPSS version 22.
Descriptive statistics were used to report differences in 
Results
Population characteristics
Efficacy
Pre-switch disease activity measures of Inflectra switch population were compared with 6 months post-switch disease activity measures of the same patients ( Figure   1 
Retention rate and safety
At 6 months post-switch, 26 (86.7%) out of 30 patients are continuing Inflectra with good efficacy and without any serious safety concern. This retention rate is lower than that of the cohorts of historic Remicade (100%)
and Inflectra (90.9%) Figure Among all observational switch studies, our trial showed the best retention rate 86.7% at 6 months. 
Conclusion
Based on the results of our real-life clinical study, we are satisfied that CT-P13 is a safe and efficacious option to treat a variety of rheumatology patients and it is reassuring that switching to CT-P13 can lead to substantial savings essential for the sustainability of the 
